**Correction to:** *Cell Death and Disease* (2014) **5**, e1239. doi:10.1038/cddis.2014.194. Published online 22 May 2014.

Since the publication of this paper. The authors have noted [Figure 1](#fig1){ref-type="fig"} was a proof reading error. The corrected figure is shown below.

The corrected article appears online together with this corrigendum. The authors would like to apologize for any inconvenience this may have caused.

![IRE1a inhibits the BMP2-induced osteogenesis assayed by ALP and OCL. (**a**) IRE1a inhibits the BMP2-dependent ALP activity in a dose-dependent manner. C2C12 cell lines and BMSCs were infected either Ad-GFP (MOI=50, serves as a control) or BMP2 (300 ng/ml) with or without IRE1a (at different MOI) for 4 days and the cell lysates were used for determining the ALP activity. (**b**) IRE1a inhibits the BMP2-dependent OCL production in a dose-dependent manner. C2C12 cell lines and BMSCs were infected as described in a and the cell culture media were used for determining the OCL level. (**c** and **e**) Expression of IRE1a and BMP2 in C2C12 and BMSCs infected with either Ad-GFP (MOI=50, serves as a control) or BMP2 (300 ng/ml) with or without IRE1a (at different MOI=10, 20, 50) for 4 days. Cell lysates were prepared from C2C12 (**c**) and BMSCs (**e**) infected with various adenoviruses, as indicated, and detected by western blotting with anti-IRE1a, anti-BMP2, and anti-tubulin (internal control) antibodies. (**d** and **f**) Semi-quantification of protein relative levels of BMP2 and IRE1a in the C2C12 (**d**) and BMSCs (**f**) infected with various adenoviruses, as indicated. Levels were normalized against those of tubulin by MJ Opticon Monitor Analysis Software (Bio-Rad); data were expressed as means±S.D. (*n*=3). Every treatment group compared with control groups, respectively, \**P*\<0.05 or \*\**P*\<0.01](cddis201599f1){#fig1}
